MYK-224
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiomyopathy, Hypertrophic
Conditions
Cardiomyopathy, Hypertrophic
Trial Timeline
Jan 18, 2023 → Feb 27, 2025
NCT ID
NCT05556343About MYK-224
MYK-224 is a phase 2 stage product being developed by Bristol Myers Squibb for Cardiomyopathy, Hypertrophic. The current trial status is terminated. This product is registered under clinical trial identifier NCT05556343. Target conditions include Cardiomyopathy, Hypertrophic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05556343 | Phase 2 | Terminated |
| NCT05686096 | Phase 1 | Completed |
| NCT05405543 | Phase 1 | Completed |
Competing Products
20 competing products in Cardiomyopathy, Hypertrophic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib + Placebo | AMO Pharma | Phase 2 | 44 |
| Mavacamten | LianBio | Phase 1 | 25 |
| Mavacamten + Placebo | LianBio | Phase 3 | 69 |
| CT-G20 + Placebo | Celltrion | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin | AstraZeneca | Approved | 85 |
| AZD0233 + AZD0233 Placebo | AstraZeneca | Phase 1 | 33 |
| AZD4063 | AstraZeneca | Phase 1 | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| candesartan | AstraZeneca | Phase 2 | 52 |
| LCZ696 + Placebo | Novartis | Phase 2 | 52 |
| Darbepoetin alfa | Amgen | Pre-clinical | 22 |
| Eleclazine + Placebo | Gilead Sciences | Phase 2/3 | 64 |
| Ranolazine | Gilead Sciences | Approved | 84 |
| Ranexa + Placebo | Gilead Sciences | Approved | 84 |
| Ranolazine | Gilead Sciences | Pre-clinical | 22 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |